Breaking News Instant updates and real-time market news.

MRTX

Mirati Therapeutics

$6.45

-0.16 (-2.42%)

07:31
10/04/16
10/04
07:31
10/04/16
07:31

Mirati Therapeutics appoints Chris LeMasters as Chief Business Officer

Mirati Therapeutics announced the appointment of Chris LeMasters to the newly created position of Executive Vice President and Chief Business Officer, effective September 30. Prior to joining Mirati, LeMasters served as the CEO of Promosome, a privately held biotherapeutics and biosimilars company. Previously, LeMasters held senior management positions at several biotherapeutics companies, most recently as co-founder and chief business officer of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company. LeMasters also served as co-founder and chief business officer of Cabrellis Pharmaceuticals, where he negotiated its acquisition by Pharmion for $104M, and as vice president, corporate development of Conforma Therapeutics, where he negotiated its acquisition by Biogen IDEC for $250M.

MRTX Mirati Therapeutics
$6.45

-0.16 (-2.42%)

06/05/16
PIPR
06/05/16
NO CHANGE
Target $14
PIPR
Neutral
Mirati update at ASCO raises tolerability concerns, says Piper Jaffray
Piper Jaffray analyst Steven Breazzano says Mirati Therapeutics ' top-line results for lead drug glesatinib at ASCO this weekend had a response rate of 27%, which is a slippage from the prior update of 50%. Tolerability, particularly diarrhea, appeared to have significantly affected efficacy with multiple dose reductions/discontinuations leading to suboptimal responses below the partial responses threshold, Breazzano tells investors in a research note. While the update may be disappointing to some investors, Mirati is evaluating a new formulation to improve bioavailability which appears promising, the analyst points out. He lowered his price target for the shares to $14 from $17 and keeps a Neutral rating on the shares.
06/06/16
JEFF
06/06/16
DOWNGRADE
Target $17
JEFF
Hold
Mirati Therapeutics downgraded to Hold from Buy at Jefferies
Jefferies analyst Brian Abrahams downgraded Mirati Therapeutics to Hold saying the lower objective response rate for lead drug glesatinib and gastrointestinal tolerability necessitating reformulation create increased risk to the drug gaining meaningful long-term market share. The analyst lowered his price target for Mirati to $17 from $27 following the company's update this weekend at ASCO.
06/06/16
LEER
06/06/16
DOWNGRADE
Target $20
LEER
Market Perform
Mirati Therapeutics downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Mirati Therapeutics to Market Perform from Outperform following updates on its lead pipeline asset, glesatinib, that he called "disappointing." The updated Phase Ib trial data in non-small cell lung cancer patients with genetic c-Met alterations included one new RECIST response in addition to two previously reported responses in now 11 patients enrolled and a 20% overall response rate, while Mirati has changed the drug's formulation due to bioavailability/tolerability issues, Schmidt noted. The analyst adds that other c-Met inhibitors have been generating promising data at ASCO and could pose potential competition. The analyst lowered his price target on Mirati shares to $20 from $37, reflecting a lower probability attributed to the potential success for glesatinib.
09/28/16
SBSH
09/28/16
NO CHANGE
Target $23
SBSH
Buy
Citi thinks JTO paper could explain recent rally in Mirati
Citi analyst Yigal Nochomovitz believes the recent move to $7 from $5 in shares of Mirati Therapeutics could be attributed to an article published online in the Journal of Thoracic Oncology on Sept. 22 titled "Emergence of pre-existing MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping". Conclusions in the JTO article may suggest some opportunity for Mirati's glesatinib in the crizotinib failure market in MET Exon14del non-small cell lung cancer, despite recent disappointing data at ASCO, Nochomovitz tells investors in a research note. The analyst has a Buy rating on Mirati with a $23 price target.

TODAY'S FREE FLY STORIES

DB

Deutsche Bank

$18.51

-0.19 (-1.02%)

08:12
01/17/18
01/17
08:12
01/17/18
08:12
Periodicals
Deutsche Bank to shift fewer London jobs than expected, Reuters reports »

Deutsche Bank expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

F

Ford

$13.10

-0.13 (-0.98%)

08:11
01/17/18
01/17
08:11
01/17/18
08:11
Technical Analysis
Technical Take: Ford down following update, FY17 and FY18 EPS view »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

VBIV

VBI Vaccines

$4.36

-0.1 (-2.24%)

08:10
01/17/18
01/17
08:10
01/17/18
08:10
Hot Stocks
VBI Vaccines doses first patient in Phase 1/2a clinical study of VBI-1901 »

VBI Vaccines announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$26.96

-0.48 (-1.75%)

08:09
01/17/18
01/17
08:09
01/17/18
08:09
Recommendations
Dermira analyst commentary  »

Dermira price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

LFUS

Littelfuse

$205.55

-0.9 (-0.44%)

, IXYS

IXYS

$23.05

-1.55 (-6.30%)

08:09
01/17/18
01/17
08:09
01/17/18
08:09
Hot Stocks
Littelfuse completes acquisition of IXYS »

Littelfuse (LFUS)…

LFUS

Littelfuse

$205.55

-0.9 (-0.44%)

IXYS

IXYS

$23.05

-1.55 (-6.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

DKS

Dick's Sporting

$32.33

-1 (-3.00%)

08:08
01/17/18
01/17
08:08
01/17/18
08:08
Technical Analysis
Technical Take: Dick's Sporting higher in pre-market, analyst action »

At time of writing, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:08
01/17/18
01/17
08:08
01/17/18
08:08
Conference/Events
Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

MGP

MGM Growth

$29.50

0.96 (3.36%)

08:08
01/17/18
01/17
08:08
01/17/18
08:08
Hot Stocks
VICI Properties rejects unsolicited proposal from MGM Growth »

VICI Properties confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEUM

Pareteum

$2.31

-0.07 (-2.94%)

08:08
01/17/18
01/17
08:08
01/17/18
08:08
Hot Stocks
Pareteum awarded $3M contract to add mobility to South American data provider »

Pareteum has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSOD

Cornerstone OnDemand

$38.94

-0.23 (-0.59%)

08:07
01/17/18
01/17
08:07
01/17/18
08:07
Hot Stocks
Cornerstone OnDemand to separate chairman and CEO roles »

Cornerstone OnDemand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 13

    Mar

ATVI

Activision Blizzard

$68.71

-1.65 (-2.35%)

, AMZN

Amazon.com

$1,304.86

-0.34 (-0.03%)

08:07
01/17/18
01/17
08:07
01/17/18
08:07
Hot Stocks
Overwatch League opening week draws more than 10M viewers »

The Overwatch League…

ATVI

Activision Blizzard

$68.71

-1.65 (-2.35%)

AMZN

Amazon.com

$1,304.86

-0.34 (-0.03%)

NTES

NetEase

$322.08

-6.75 (-2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 07

    Feb

  • 08

    Feb

  • 18

    Mar

KNX

Knight-Swift

$44.63

-0.37 (-0.82%)

08:07
01/17/18
01/17
08:07
01/17/18
08:07
Conference/Events
Knight-Swift management to meet with Deutsche Bank »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 30

    Jan

MPLX

MPLX

$38.28

-0.5 (-1.29%)

08:07
01/17/18
01/17
08:07
01/17/18
08:07
Hot Stocks
MPLX announces joint open season for Cushing-to-Patoka pipeline expansion »

MPLX announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$232.90

4.26 (1.86%)

08:06
01/17/18
01/17
08:06
01/17/18
08:06
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$167.54

-1.76 (-1.04%)

08:06
01/17/18
01/17
08:06
01/17/18
08:06
Recommendations
Deere analyst commentary  »

Deere price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

RIOT

Riot Blockchain

$18.28

-3.6 (-16.45%)

08:05
01/17/18
01/17
08:05
01/17/18
08:05
Hot Stocks
Riot Blockchain's Tess Pay signs agreement for Cresval Capital transaction »

Riot Blockchain's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

WAFD

Washington Federal

$35.60

-0.05 (-0.14%)

08:05
01/17/18
01/17
08:05
01/17/18
08:05
Earnings
Washington Federal reports Q4 EPS 59c, consensus 51c »

Return on equity for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICHR

Ichor Holdings

$25.60

0.86 (3.48%)

08:05
01/17/18
01/17
08:05
01/17/18
08:05
Earnings
Ichor Holdings sees Q1 revenue $240M-$250M, consensus $208.35M »

For 1Q18, Ichor expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OBE

Obsidian Energy

08:04
01/17/18
01/17
08:04
01/17/18
08:04
Hot Stocks
FrontFour Capital voices concerns regarding Obsidian Energy »

FrontFour Capital Group,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$54.90

0.07 (0.13%)

08:04
01/17/18
01/17
08:04
01/17/18
08:04
Downgrade
HSBC rating change  »

HSBC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICHR

Ichor Holdings

$25.60

0.86 (3.48%)

08:04
01/17/18
01/17
08:04
01/17/18
08:04
Earnings
Ichor Holdings sees Q4 revenue $183M, consensus $181.17M »

Ichor Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

RGC

Regal Entertainment

$22.90

-0.07 (-0.30%)

08:03
01/17/18
01/17
08:03
01/17/18
08:03
Downgrade
Regal Entertainment rating change  »

Regal Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.55 (-2.93%)

08:03
01/17/18
01/17
08:03
01/17/18
08:03
Hot Stocks
GE Transportation signs locomotive, service agreements valued at over $900M »

GE Transportation signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DWDP

DowDuPont

$74.95

-0.46 (-0.61%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
DowDuPont, UC Davis team up to advance orphan African crops »

Dow AgroSciences teamed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.